These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 19062016)

  • 21. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
    Chiba Y; Onouchi T; Ikeda T; Adachi J; Tamura Y; Horiuchi T
    Gerontology; 2009; 55(3):275-80. PubMed ID: 19158438
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The OPG/RANKL system and zinc ions are promoters of bone remodeling by osteoblast proliferation in postmenopausal osteoporosis.
    Gurban CV; Mederle O
    Rom J Morphol Embryol; 2011; 52(3 Suppl):1113-9. PubMed ID: 22119834
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial.
    Anastasilakis AD; Goulis DG; Polyzos SA; Gerou S; Koukoulis G; Kita M; Avramidis A
    Horm Metab Res; 2008 Apr; 40(4):281-5. PubMed ID: 18275008
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity.
    Kim SM; Lee J; Ryu OH; Lee KW; Kim HY; Seo JA; Kim SG; Kim NH; Baik SH; Choi DS; Choi KM
    Clin Endocrinol (Oxf); 2005 Nov; 63(5):594-8. PubMed ID: 16268814
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of osteoprotegerin with aortic stiffness in patients with symptomatic peripheral artery disease and in healthy subjects.
    Zagura M; Serg M; Kampus P; Zilmer M; Zilmer K; Eha J; Unt E; Lieberg J; Kals J
    Am J Hypertens; 2010 Jun; 23(6):586-91. PubMed ID: 20224558
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of risedronate treatment on serum osteoprotegerin and bone marker levels in postmenopausal women with osteoporosis.
    Karadag-Saygi E; Akyuz G; Bizargity P; Ay P
    Gynecol Endocrinol; 2011 Dec; 27(12):1033-6. PubMed ID: 21627558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of 12-months treatment with zoledronate or teriparatide on intima-media thickness of carotid artery in women with postmenopausal osteoporosis: A pilot study.
    Passeri E; Mazzaccaro D; Sansoni V; Perego S; Nano G; Verdelli C; Lombardi G; Corbetta S
    Int J Immunopathol Pharmacol; 2019; 33():2058738418822439. PubMed ID: 30791743
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Osteoprotegerin is Associated With Endothelial Function and Predicts Early Carotid Atherosclerosis in Patients With Coronary Artery Disease.
    Morisawa T; Nakagomi A; Kohashi K; Kosugi M; Kusama Y; Atarashi H; Shimizu W
    Int Heart J; 2015; 56(6):605-12. PubMed ID: 26549398
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of serum osteoprotegerin levels with carotid-femoral pulse wave velocity in hypertensive patients.
    Wang JH; Lee CJ; Chen ML; Yang CF; Chen YC; Hsu BG
    J Clin Hypertens (Greenwich); 2014 Apr; 16(4):301-8. PubMed ID: 24640954
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circulating androgen levels are associated with subclinical atherosclerosis and arterial stiffness in healthy recently menopausal women.
    Creatsa M; Armeni E; Stamatelopoulos K; Rizos D; Georgiopoulos G; Kazani M; Alexandrou A; Dendrinos S; Augoulea A; Papamichael C; Lambrinoudaki I
    Metabolism; 2012 Feb; 61(2):193-201. PubMed ID: 21820132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Independent relationship of osteoprotegerin concentrations with endothelial activation and carotid atherosclerosis in patients with severe rheumatoid arthritis.
    Dessein PH; López-Mejias R; González-Juanatey C; Genre F; Miranda-Filloy JA; Llorca J; González-Gay MA
    J Rheumatol; 2014 Mar; 41(3):429-36. PubMed ID: 24488413
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship between circulating serum osteoprotegerin and total receptor activator of nuclear κ-B ligand levels, triglycerides, and coronary calcification in postmenopausal women.
    Poornima IG; Mackey RH; Buhari AM; Cauley JA; Matthews KA; Kuller LH
    Menopause; 2014 Jul; 21(7):702-10. PubMed ID: 24473535
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiac biomarkers and noninvasive predictors of atherosclerosis in chronic peritoneal dialysis patients.
    Caliskan Y; Ozkok A; Akagun T; Alpay N; Guz G; Polat N; Tufan F; Ecder T; Bozfakioglu S
    Kidney Blood Press Res; 2012; 35(5):340-8. PubMed ID: 22473007
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The relationship between inflammation and arterial stiffness in patients with essential hypertension.
    Kampus P; Muda P; Kals J; Ristimäe T; Fischer K; Teesalu R; Zilmer M
    Int J Cardiol; 2006 Sep; 112(1):46-51. PubMed ID: 16297996
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adiponectin and arterial stiffness.
    Mahmud A; Feely J
    Am J Hypertens; 2005 Dec; 18(12 Pt 1):1543-8. PubMed ID: 16364823
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum osteoprotegerin is a predictor of progression of atherosclerosis and coronary calcification in hemodialysis patients.
    Kurnatowska I; Grzelak P; Kaczmarska M; Stefańczyk L; Nowicki M
    Nephron Clin Pract; 2011; 117(4):c297-304. PubMed ID: 20861651
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Receptor activator of NF(Kappa)B ligand/osteoprotegerin (RANKL/OPG) system and osteopontin (OPN) serum levels in a population of apulian postmenopausal women.
    D'Amore M; Fanelli M; D'Amore S; Fontana A; Minenna G
    Panminerva Med; 2006 Dec; 48(4):215-21. PubMed ID: 17215793
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis.
    Yano K; Tsuda E; Washida N; Kobayashi F; Goto M; Harada A; Ikeda K; Higashio K; Yamada Y
    J Bone Miner Res; 1999 Apr; 14(4):518-27. PubMed ID: 10234572
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Circulating osteoprotegerin is increased in the metabolic syndrome and associates with subclinical atherosclerosis and coronary arterial calcification.
    Pérez de Ciriza C; Moreno M; Restituto P; Bastarrika G; Simón I; Colina I; Varo N
    Clin Biochem; 2014 Dec; 47(18):272-8. PubMed ID: 25218813
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elevated osteoprotegerin is associated with inflammation, malnutrition and new onset cardiovascular events in peritoneal dialysis patients.
    Koo HM; Do HM; Kim EJ; Lee MJ; Shin DH; Kim SJ; Oh HJ; Yoo DE; Kim JK; Park JT; Han SH; Kang SW; Choi KH; Yoo TH
    Atherosclerosis; 2011 Dec; 219(2):925-30. PubMed ID: 22015178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.